Nyrada Inc.

Nyrada Inc. is a preclinical-stage biotechnology company focused on the discovery and development of novel small molecule drugs targeting cardiovascular and neurological diseases. Headquartered in Sydney, the company’s research programs center on innovative therapies for cholesterol management and the treatment of secondary brain injury following stroke or traumatic brain injury, addressing significant unmet medical needs in these areas. Nyrada Inc. operates within the pharmaceuticals and biotechnology sector, contributing to advancements in health technology through its specialized drug development pipeline. The company is listed on the CHI-X Market Australia – Limit Venue, an alternative trading platform that provides efficient access to Australian equities and supports competitive market dynamics. Nyrada Inc. continues to play a role in the evolving landscape of biotech innovation, with its progress closely followed by investors and industry stakeholders.